

17 June 2026

Osteopore delivers first order to support dental product launch by DKSH in Malaysia

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX:OSX; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the first delivery of dental products following the signing of a five year partnership with DKSH Malaysia Sdn Bhd, a subsidiary of DKSH Holding Ltd (SIX:DKSH).

As previously announced on 25 November 2025¹, Osteopore entered into a five-year agreement with DKSH for the distribution of its dental product portfolio in Malaysia. The first product delivery marks an important milestone in the execution of the partnership and the commercial expansion of Osteopore's dental business in the Malaysian market. The initial product delivery represents the commencement of commercial activities under the agreement and reflects the successful implementation of Osteopore strategy to expand its presence in the rapidly growing dental regeneration market across Southeast Asia.

The dental products delivered in this first order are off-the-shelf products designed to assist in a surgical procedure known as Guided Bone Regeneration (GBR) where a combination of membrane, bone grafts, and/or bone substitutes are used to encourage new bone growth in areas where there is insufficient bone volume.

¹ ASX announcement, "OSX partners DKSH for dental products in Malaysia", 25 November 2025.



Based on a market research report³, the Malaysian GBR and Guided Tissue Regeneration market is projected to reach around USD\$60 million by 2028 with a CAGR of 6.3%. Growth drivers include medical tourism and increasing awareness of periodontal health. Bioresorbable membranes and enhanced regenerative materials are also reported to be gaining traction in Malaysia.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

³ Market Research Intellect, "Guided Tissue Regeneration Gtr Membrane Market by Applications: Malaysia, Germany, Japan, Canada, Hong Kong", 9 September 2025.



Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

